TransMedics to Report Fourth Quarter and Full Year 2022 Financial Results on February 22, 2023
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
TransMedics Group, Inc. (NASDAQ: TMDX) will announce its fourth quarter and full year 2022 financial results on February 22, 2023, after market close. A conference call will follow at 4:30 p.m. ET. Investors can access the call by dialing (866) 807-9684 domestically or (412) 317-5415 internationally. TransMedics specializes in portable extracorporeal warm perfusion and organ assessment technology, aimed at improving organ transplantation outcomes for patients suffering from end-stage heart, lung, and liver diseases.
Positive
- Focus on enhancing organ viability and transplantation outcomes.
- Scheduled release of Q4 and full year 2022 financial results indicates transparency.
Negative
- None.
Details
News Market Reaction – TMDX
The recorded move for TMDX in the trading session of this news was -1.29%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
Investors interested in listening to the conference call may do so by dialing (866) 807-9684 for domestic callers or (412) 317-5415 for international callers and ask to be joined into the
About
Investor Contact:
332-895-3222
Investors@transmedics.com
View original content to download multimedia:https://www.prnewswire.com/news-releases/transmedics-to-report-fourth-quarter-and-full-year-2022-financial-results-on-february-22-2023-301740471.html
SOURCE
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.